Aptargroup, Inc DEF 14A, filed Mar 28, 2025

About this DEF 14A

Aptargroup, Inc. (ATR)

DEF 14A 2025-03-28 For: 2025-05-07

View Original

Added on June 12, 2026

Board Member:

Requirement:

Current
Required Value:

Non-Executive
Director

Annual
Cash
Retainer

Aptargroup, Inc filed this DEF 14A on March 28, 2025.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material under §240.14a-12


AptarGroup, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):
☒	No fee required.
☐	Fee paid previously with preliminary materials.
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



DATE AND TIME	PLACE	RECORD DATE
9:00 a.m. CDT on Wednesday, May 7, 2025	Live webcast online at www.virtualshareholdermeeting.com /ATR2025	March 14, 2025


		Board Voting Recommendation
Proposal No. 1: To elect the three director nominees named in the proxy statement to terms of office expiring at the annual meeting in 2028		FOR each
Proposal No. 2: To approve, on an advisory basis, Aptar’s executive compensation		FOR
Proposal No. 3: To approve an amendment to the 2018 Equity Incentive Plan		FOR
Proposal No. 4: To ratify the appointment of the independent registered public accounting firm for 2025		FOR


	Internet (Preferred)		Telephone		Mail	Mark, sign and date your proxy card and return it in the pre-addressed postage paid envelope we have provided or return it to:

Visit www.proxyvote.com up until 11:59 p.m. EDT, on May 6, 2025		Call the telephone number on your proxy card		Vote Processing, c/o Broadridge 51 Mercedes Way Edgewood, NY 11717


ELECTRONIC DELIVERY OF MATERIALS	2
PROXY SUMMARY	3
PROPOSAL 1—ELECTION OF DIRECTORS	12
Nominees for Election	13
Directors Whose Present Terms Continue	15
Corporate Governance	19
Board Meeting Attendance	27
Board Compensation	28
PROPOSAL 2—ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION	30
PROPOSAL 3—APPROVAL OF AN AMENDMENT TO THE 2018 EQUITY INCENTIVE PLAN	31
PROPOSAL 4—RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2025	38
Independent Registered Public Accounting Firm Fees	39
EXECUTIVE OFFICER COMPENSATION	40
Compensation Discussion and Analysis	40
Compensation Committee Report	54
2024 Summary Compensation Table	55
2024 Grants of Plan-Based Awards	58
2024 Outstanding Equity Awards at Fiscal Year-End	59
2024 Option Exercises and Stock Vested	61
Employment Agreements	62
Pension Benefits	64
Potential Payments upon Termination of Employment	67
CEO Pay Ratio	71
Pay Versus Performance	72
EQUITY COMPENSATION PLAN INFORMATION	77
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND MANAGEMENT	78
TRANSACTIONS WITH RELATED PERSONS	80
DELINQUENT SECTION 16(a) REPORTS	81
AUDIT COMMITTEE REPORT	82
OTHER MATTERS	83
Proxy Solicitation	83
Annual Report/Form 10-K	83
Stockholder Proposals and Nominations	83
FREQUENTLY ASKED QUESTIONS	84
How do I attend?	84
Who is entitled to vote?	84
May stockholders ask questions at the virtual annual meeting?	84
What if I have technical difficulties or trouble accessing the virtual annual meeting?	84
What am I voting on and how does the Board of Directors recommend I vote on the proposals?	85
How do I vote?	85
What is a quorum?	85
How are shares in a 401(k) plan voted?	86
How are shares held in a broker account voted?	86
How many votes are required to approve each proposal?	86
Who will count the votes?	86
How can I help reduce the environmental impact of the annual meeting?	86
Appendix A – AptarGroup, Inc. 2018 Equity Incentive Plan	A-1


	Help us “go green” and reduce costs. For those stockholders who are still receiving paper copies of our proxy statement and annual report, please consider requesting electronic delivery or a Notice of Internet Availability of Proxy Materials (“Notice”), which will reduce the amount of paper materials needed to conduct our annual meeting. You may do so by following the instructions below.
AptarGroup, Inc. (“Aptar” or “Company”) is pleased to take advantage of the Securities and Exchange Commission ("SEC") rule allowing companies to furnish proxy materials to their stockholders over the Internet. We believe that this e-proxy process expedites stockholders’ receipt of proxy materials, while also lowering the costs and reducing the environmental impact of our annual meeting. On March 28, 2025, we mailed to most of our stockholders a Notice containing instructions on how to access our proxy statement and annual report and vote online. On the same date, we mailed to all other stockholders a copy of the proxy statement and annual report by mail unless they have elected to receive the annual meeting materials over the Internet.

HOW TO ENROLL
Stockholders of Record (your shares of common stock are registered directly in your name with EQ Shareowner Services, our transfer agent) Visit www.proxyvote.com or scan the QR code above to vote your shares. When prompted, indicate that you agree to receive or access proxy materials electronically in the future. Beneficial Owners (your shares are held in “street name” in an account at a brokerage firm, bank, broker-dealer or other similar organization) Follow the instructions provided by your broker, bank or other intermediary to opt in to electronic delivery.


Separate independent Chair & CEO	100% Independent Audit, Management Development and Compensation, and Corporate Governance Committees	Director age limits


Directors and executive officers are prohibited from hedging or pledging stock	Stock ownership requirements for directors and executive officers	Majority voting for directors and director resignation policy in uncontested elections


Annual “Say-on-Pay Vote” on executive compensation	Independent directors meet regularly in executive session	Annual Board and Committee self-evaluations

Our compensation philosophy is designed to fairly reward our executives for growing our business and increasing value for stockholders, and to retain our experienced management team.	Significant amount of pay that is performance-based and/or at-risk, with emphasis on performance-based pay to reward short-and long-term performance measured against pre-established objectives and a substantial amount provided in equity

		Employment and change-in-control agreements that are designed to be competitive in markets in which we compete for executive talent		Absence of tax gross-up agreements with named executive officers, other than those related to relocation benefits or expatriate assignments

Stock ownership guidelines, limits on executive officer stock trading and prohibition of hedging or pledging Aptar equity securities	Use of an independent compensation consultant		Limited perquisites other than common perquisites provided in the context of expatriate assignments or related to relocation



We have been named as one of the World’s Top Companies for Women by Forbes for the fourth consecutive year.	We strive to promote and sustain a sense of belonging for all individuals. We support and promote the development of every employee as we aspire for a more inclusive workplace.	We aim to cultivate an open culture founded on fairness and a sense of belonging rooted in our core values of mutual trust and respect. Our employee resource groups, which are open to all employees, provide an open and inclusive forum to facilitate exchange and growth.


Aptar has partnered with CARE®, a 501(c)(3) organization that works around the globe to save lives, defeat poverty and achieve social justice. CARE’s mission aligns with our purpose, values and mission to further inclusion, equity and belonging to support the communities where we live and work, along with global communities most in need and other emergency efforts.


Recognitions	Our Performance 2024-2025
Barron’s	Included on Barron’s 2025 list of 100 Most Sustainable Companies in the U.S., marking our 7^th consecutive year on the list.	*
CDP	Recognized for leadership on climate change topics by the global environmental non-profit CSP, securing a place on its prestigious ‘A List’
CDP	Named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year
Ecovadis	Awarded the coveted top 1% Platinum scoring for our achievements in the areas of environment, labor and human rights, ethics and sustainable procurement.
Forbes	Named Among Top 50 or World’s Top Companies for Women 2024 by Forbes.
Newsweek	Named one of America’s Most Responsible Companies by Newsweek for the sixth consecutive year
Time	Named One of the World’s Most Sustainable Companies 2024 by Time
USA Today	Named one of America’s Climate Leaders 2024 by USA Today


	The Board of Directors recommends a vote FOR each of the following nominees for director.



	GEORGE L. FOTIADES Age: 71 Independent Director since: 2011 Committees: Audit
Career Highlights Mr. Fotiades was the Chairman of the Board of Aptar from May 2018 to May 2023. He has served as Executive Chairman of Elio Health, a private investment firm, since he co-founded the firm in 2022. Mr. Fotiades was the President and CEO of Cantel Medical Corp. (a NYSE-listed manufacturer of infection prevention and control products) from March 2019 until its acquisition by STERIS plc in June 2021. Mr. Fotiades was an Operating Partner in the healthcare practice of Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 to March 2019. From 2007 to April 2017, he was a partner of Healthcare Investments at Diamond Castle Holdings LLC (private equity investing). Mr. Fotiades was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. He is currently a director of Prologis, Inc. (a NYSE-listed integrated distribution facilities and services) and previously was a director of Cantel Medical Corp. The Board of Directors concluded that Mr. Fotiades should continue to serve as a director of Aptar due to his extensive experience in leading healthcare and consumer product companies, including serving as President and Chief Operating Officer of Cardinal Health, Inc., as well as other senior executive positions at Catalent Pharma Solutions, the former Warner-Lambert’s Consumer Health Products Group and Bristol-Myers Squibb’s Consumer Products, Japan division. The Board also considered his present and past board level experience with global organizations. This experience has also led the Board to determine that Mr. Fotiades is an “audit committee financial expert” as defined by the SEC.

	THE ENVIRONMENT


	OUR SOCIETY


	GOOD CORPORATE GOVERNANCE



	CANDACE MATTHEWS Age: 66 Independent Director since: 2021 Committees: Corporate Governance
Career Highlights Ms. Matthews has been the Chair of Aptar’s Board since May 2023. Ms. Matthews is the former Chief Reputation Officer for Amway Corp. (a company that sells health, beauty and home care products), having served in that role from June 2020 to June 2021, responsible for overseeing Amway’s global reputation strategy and corporate social responsibility. Prior to those roles, Ms. Matthews spent six years as Regional President of the Americas at Amway, heading all operations in North, Central and South America. Prior to joining Amway in 2007 as Chief Marketing Officer, Ms. Matthews served in executive positions at established multinational beauty companies, served as President of the SoftSheen-Carson, Consumer Products Division of L’Oréal USA, held a leadership role at The Coca-Cola Company and an innovation role at CIBA Vision Corporation. She also worked for several other notable companies such as Bausch + Lomb, Procter & Gamble and General Mills. Ms. Matthews currently serves on the board of directors of Société BIC S.A. (a consumer product manufacturer) and Corewell Health Foundation (formerly Spectrum Health Foundation). Ms. Matthews is a former director of MillerKnoll, Inc. (formerly Herman Miller, Inc.) (a modern furniture design company), and Popeye’s Louisiana Kitchen Inc. (a U.S. restaurant chain). The Board of Directors concluded that Ms. Matthews should continue to serve as a director of Aptar in part due to her executive background as a senior marketing executive of leading beauty and consumer products organizations, her public company director experience, her knowledge of, and background in, the beauty and consumer goods industry and her strategic planning, governance, finance and senior management experience.



	B. CRAIG OWENS Age: 70 Independent Director since: 2018 Committees: Audit (Chair), Management Development and Compensation
Career Highlights Mr. Owens was the Chief Financial Officer and Chief Administrative Officer of The Campbell’s Company (global producer and seller of canned soups and related products) from 2008 to 2014. Mr. Owens is a director of Crown Holdings, Inc. (a NYSE-listed designer, manufacturer and seller of packaging products and equipment for consumer goods and industrial products). He is a former director of Dean Foods Company (a U.S. food and beverage company) and J. C. Penney Company, Inc. (a U.S. department store chain). The Board of Directors concluded that Mr. Owens should continue to serve as a director of Aptar due to his extensive experience in the consumer food and beverage industries, as well as his significant expertise in financial reporting, accounting, corporate finance and capital markets. This experience has also led the Board to determine that Mr. Owens is an “audit committee financial expert” as defined by the SEC.



	JULIE XING Age: 56 Independent Director since: 2023 Committees: Management Development and Compensation
Career Highlights Dr. Xing has served as Executive Chair of the Board of Directors of Mundipharma China since 2022. Mundipharma is a multinational pharmaceutical leader. From 2019 to 2022, Dr. Xing held the position of Global Senior Vice President, President of Greater China for Envista Holdings Corporation (a dental equipment and supplies company). Prior to that, Dr. Xing served in numerous leadership roles at Eli Lilly and Company (a global pharmaceutical company), including Senior Director, Global New Product Planning and Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2018 to 2019, Senior Director, Global Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2015 to 2018, Vice President of Lilly China Oncology from 2012 to 2014 and Vice President of Corporate and Government Affairs and Market Access from 2010 to 2012, while based in Shanghai. Prior to Eli Lilly, from 2007 to 2010 Dr. Xing was Vice President and General Manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific. Dr. Xing was General Manager and China President of Illumina (a global next generation gene sequencer company) from 2005 to 2007. Dr. Xing has served as a Board advisor of Lee Kum Kee Group (privately-held global manufacturer of sauces and condiments), since February 2025. Dr. Xing also served as Board advisor to the Board of Directors of Mars, Incorporated (a global manufacturer of confectionery, pet food and provider of animal care services) from 2019 to 2024. Dr. Xing has a PhD in biology from the Hong Kong University of Science and Technology. The Board of Directors concluded that Dr. Xing should continue to serve as a director of Aptar due to her board leadership acumen, along with her in depth knowledge of the pharmaceutical market and the Asia region.



	SARAH GLICKMAN Age: 55 Independent Director since: 2023 Committees: Audit
Career Highlights Ms. Glickman has over 30 years of global financial and operational experience, including in the pharmaceutical industry, and is currently the Chief Financial Officer and Principal Accounting Officer of Criteo S.A., a global commerce media company, since September 2020. She previously held the position of Acting Chief Financial Officer at XPO, Inc., a leading global provider of transportation and logistics solutions, where she previously served as Senior Vice President, Corporate Finance and Transformation. She also held global executive roles at Novartis, Honeywell International and Bristol-Myers Squibb and started her career at PricewaterhouseCoopers. Since 2021, Ms. Glickman has served on the Board of Directors and is Chair of the Audit Committee for 2seventy bio, Inc., a biotech company (previously part of bluebird bio, Inc.) Ms. Glickman joined Aptar’s Board of Directors in 2023. The Board of Directors concluded that Ms. Glickman should continue to serve as a director of Aptar due to her expertise in public company finance, accounting, strategic planning and risk management, having served in senior executive and financial oversight roles in various public companies. This experience has also led the Board to determine that Ms. Glickman is an “audit committee financial expert” as defined by the SEC.



	MATT TREROTOLA Age: 57 Independent Director since: 2022 Committees: Corporate Governance (Chair)
Career Highlights Mr. Trerotola has served as the Chief Executive Officer for Enovis Corporation since April 2022 and as President and Chief Executive Officer of its predecessor Colfax Corporation from July 2015 to April 2022. He has served as Chair of the board of directors of Enovis since May 2023. Enovis is an innovation-driven medical technology company formed when Colfax separated from its industrial businesses and was renamed. Prior to joining Enovis, from 2014 to 2015, Mr. Trerotola was an Executive Vice President and a member of the Office of the Chief Executive at DuPont de Nemours, Inc. (a global innovation leader with technology-based materials and solutions) and from 2013 to 2014 he served as Senior Vice President. While at DuPont, he was responsible for DuPont’s Electronics & Communications and Safety & Protection segments (2014), and he also had corporate responsibility for DuPont’s Asia-Pacific business. Prior to joining DuPont in 2013, Mr. Trerotola served in leadership roles at Danaher Corporation (a global science and technology innovator), since 2007, and was most recently Vice President and Group Executive for Life Sciences. Mr. Trerotola has served as a director of Enovis since 2015. The Board of Directors concluded that Mr. Trerotola should continue to serve as a director of Aptar due to his experience leading a publicly traded medical technology company and working with large global companies such as DuPont and Danaher. The Board also considered Mr. Trerotola’s extensive background in operations and strategy across various industries including healthcare, medical technologies and regulated markets, as well as emerging markets, change management and digital strategy.



	RALF K. WUNDERLICH Age: 58 Independent Director since: 2009 Committees: Management Development and Compensation
Career Highlights Mr. Wunderlich has served as the President and CEO of Huhtamaki Oyj (a Nasdaq Helsinki-listed global food packaging company) since January 2025. Prior to this role, he was an independent consultant and a senior advisor to private equity firms. He is currently the Chair of the Board of Directors of Shepherd Building Group Ltd. (a privately held U.K. construction company). Until January 2025, Mr. Wunderlich served as a director of Huhtamaki Oyj, Essentra PLC (an LSE-listed manufacturer and distributor of essential industrial components) and Klöckner Pentaplast (a privately held international manufacturer of plastic packaging products for the pharma, healthcare and food industries headquartered in Luxembourg). He is a former member of Amcor Limited’s Global Executive Team and former President of the business group Amcor Flexibles Asia Pacific (packaging solutions including healthcare and pharma packaging). Mr. Wunderlich also formerly served as a director of LINPAC Group and AMVIG Group. The Board of Directors concluded that Mr. Wunderlich should continue to serve as a director of Aptar in part due to his senior executive positions at leading global packaging companies, his knowledge of and background in the packaging industry and his international experience in working with and from various European, American and Asian countries.


Human Capital		Inclusion, Equity & Belonging
Our key human capital management objectives are to attract, retain and develop the highest quality talent. To support these objectives, our human resources programs are designed to develop talent to prepare them for critical roles and leadership positions for the future; reward and support employees through competitive pay, benefit, and incentive programs; enhance our culture through efforts aimed at making the workplace more engaging and inclusive; acquire talent and facilitate internal talent mobility to create a high-performing, diverse workforce; and evolve and invest in technology, tools, and resources to enable employees at work.		We aim to cultivate an open culture founded on fairness and a sense of belonging rooted in our core values of mutual trust and respect. We support and promote the development of every employee as we aspire for a more inclusive workplace. Our employee resource groups, which are open to all employees, provide an open and inclusive forum to facilitate exchange and growth.


Skill / Experience	Fotiades	Glickman	Marey-Semper	Matthews	Monnas	Owens	Tanda	Trerotola	Wunderlich	Xing
Executive Leadership
Public Company Governance
International/ Global Experience
Industry Experience (Pharma/Medical Technology/ Consumer Products/ Packaging)
Financial Expertise/ Literacy; Risk Management
Strategy/M&A/ Transformation
Digital Technology/ Cyber
Human Capital/ Executive Compensation/ Talent Management
Sustainability
Commercial (Sales/Marketing)
Manufacturing/ Supply Chain
R&D/Product Innovation

Audit		The Board has three primary committees, all with the following characteristics: · Governed by a written charter approved by the Board · Comprised solely of independent directors · Decisions and actions reported to the full Board following each meeting An affirmative vote of at least 70% of the Board is required to change the size, membership or powers of these committees, to fill vacancies in them, or to dissolve them.

Management Development & Compensation

Corporate Governance


Audit Committee
Members:	Meetings held in 2024: 8
B. Owens, Chair G. Fotiades S. Glickman
Key Characteristics and Responsibilities: ● Each member satisfies the heightened independence standards applicable to audit committee service ● Each member is an “audit committee financial expert” as defined by the SEC ● Oversees the financial reporting process, system of internal controls and audit process ● Reviews annual and interim financial statements	● Reviews the qualifications, independence and audit scope of the independent registered public accounting firm ● Responsible for the appointment, retention, termination, compensation and oversight of the Company’s independent registered public accounting firm ● Reviews process for monitoring compliance with laws, regulations and the Code of Conduct and compliance risks, including related to cybersecurity and business continuity ● Approves all related person transactions in accordance with the Related Person Transactions Policy ● Reviews the Company’s controls with regard to environment, social and governance disclosures in SEC filings ● Reviews and discusses with management, internal audit and external specialists, as appropriate, the Company’s controls, procedures and processes regarding cybersecurity, and oversees the process for disclosure regarding cybersecurity incidents in SEC filings


Management Development and Compensation Committee
Members:	Meetings held in 2024: 6
G. Kampouri Monnas, Chair B. Owens R. Wunderlich J. Xing
Key Characteristics and Responsibilities: ● Each member satisfies the heightened independence standards applicable to compensation committee service ● Discharges the Board’s responsibilities relating to compensation of the Company’s executives ● Reviews and recommends to the Board compensation plans, policies and programs ● Approves CEO and executive officer compensation, and employment and severance agreements, including change-in-control provisions ● Provides input and recommendations to the Board regarding the performance objectives for the CEO and other executive officers and their actual performance against such objectives ● Annually reviews the succession plans affecting corporate and other key management positions ● Reviews periodically the Company’s key human resources policies and practices relating to talent sourcing, talent development programs, and organizational engagement and effectiveness	● Monitors the Company’s policies, objectives and programs related to inclusion, equity and belonging, and reviews periodically the Company’s progress ● Reviews changing legislation and trends relating to compensation and broader management practices and evaluates impact on the Company ● Approves grants and/or awards of stock options, restricted stock units, performance-based units, and other forms of equity-based compensation ● Receives recommendations annually from the CEO regarding the compensation levels of our other executive officers, including salary, annual performance incentives and equity compensation ● Oversees the implementation of Aptar’s Policy on Recoupment and Forfeiture of Incentive Compensation (i.e., clawback policy) ● None of the members in 2024 had interlocking relationships within the meaning of SEC rules


Corporate Governance Committee
Members:	Meetings held in 2024: 4
M. Trerotola, Chair I. Marey-Semper C. Matthews
Key Characteristics and Responsibilities: ● Comprised solely of independent directors ● Identifies, evaluates and recommends to the Board individuals qualified to stand for election as directors, including nominations received from Board members, stockholders or outside parties ● Develops and recommends to the Board Aptar’s Corporate Governance Principles and standards to be applied in determining director independence ● Oversees annual evaluations of the Board, its committees and management, and the effectiveness of the Board as a working group	● Reviews and recommends to the Board appropriate compensation for non-employee directors, taking into consideration, among other items, director compensation levels of companies with similar annual revenues as Aptar ● Makes recommendations to the Board regarding changes to the size and composition of the Board or any Board committee ● Reviews the Company's efforts with regard to environmental, social, and governance matters, including with respect to the Company's annual sustainability report


		Our Corporate Governance Principles provide that the Board must be composed of a substantial majority of independent directors with an objective of having the Board consist entirely of independent directors (other than the CEO). No director qualifies as independent unless the Board affirmatively determines that the director has no material relationship with Aptar either directly or indirectly as a partner, stockholder or officer of an organization that has a relationship with Aptar.


Director	Independent
G. Fotiades	✔
S. Glickman	✔
G. Kampouri Monnas	✔
I. Marey-Semper	✔
C. Matthews	✔
B. Owens	✔
M. Trerotola	✔
R. Wunderlich	✔
J. Xing	✔
S. Tanda*


Name	Audit	Management Development and Compensation	Corporate Governance
G. Fotiades (I)	M
S. Glickman (I)	M
G. Kampouri Monnas (I)		C
I. Marey-Semper (I)			M
C. Matthews (I)			M
B. Owens (I)	C	M
M. Trerotola (I)			C
S. Tanda
R. Wunderlich (I)		M
J. Xing (I)		M
Number of Meetings in 2024	8	6	4


	Fees Earned		All Other
	or Paid in Cash	Stock Awards	Compensation	Total
Name	($)	($)(1)	($)(2)	($)
G. Fotiades	111,000	160,072		271,072
S. Glickman	111,000	160,072		271,072
G. Kampouri Monnas	122,000	160,072	2,000	284,072
I. Marey-Semper	107,000	160,072		267,072
C. Matthews	212,500	187,541		400,041
B. Owens	135,000	160,072	6,000	301,072
M. Trerotola	117,000	160,072	2,000	279,072
R. Wunderlich	107,000	160,072		267,072
J. Xing	107,000	160,072		267,072


Name and Position		Stock Options	Stock Appreciation Rights	Restricted Stock	Restricted Stock Units⁽¹⁾
Stephan B. Tanda, President and CEO		104,022	−	−	297,710
Robert Kuhn, Executive Vice President, CFO		25,831	−	−	95,526
Gael Touya, President of Aptar Pharma		18,909	−	−	65,281
Marc Prieur, President of Aptar Beauty		20,555	−	−	66,909
Hedi Tlili, President of Aptar Closures		18,181			46,995
Xiangwei Gong, Executive Vice President, Strategic Group and President of Aptar Asia		16,378	−	−	63,965
All executive officers (9 persons)		241,154	−	−	745,932
All non-executive directors (9 persons)		−	−	−	56,244
All employees (other than current executive officers)		323,656	−	−	1,729,592
(1)	Included in this column are 1,222,527 PRSUs (at target). Under the terms of the PRSU award agreements, the vesting level of the PRSU may range from 0% to 250% based on Aptar’s performance during the three-year performance period.


	The Board of Directors and the Audit Committee recommend a vote FOR the ratification of the appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for 2025.